El-Hagracy Rehab S, Kamal Gihan M, Sabry Inas M, Saad Abeer A, Abou El Ezz Nahla F, Nasr Hesham A R
Oman Med J. 2010 Jul;25(3):173-8. doi: 10.5001/omj.2010.52.
Tissue factor (TF) is the main initiator of the extrinsic coagulation pathway through factor VII (FVII) activation, which is physiologically inhibited by tissue factor pathway inhibitor (TFPI). Alteration of this pathway has been described in Type 2 diabetes mellitus (T2DM). The aim of this study is to assess TF and TFPI plasma levels and FVII coagulant activity (FVIIa) in T2DM in relation to cardiothrombotic disease and their correlation to metabolic and clinical behavior of the patients.
The study was conducted on 80 T2DM patients divided to accordingly; groupI: 40 patients without a history or clinically detected heart disease, and groupII: 40 patients with a history of myocardial infarction compared to 30 controls. The patients were recruited from Ain Shams University diabetes clinic from September 2007 to February 2009 after informed consent was obtained. Peripheral blood samples were taken for measurement of plasma TF and TFPI levels using ELISA technique and quantitative FVIIa using FVII deficient plasma.
Plasma levels of TF, TFPI and FVIIa were significantly higher in T2DM patients compared to the controls (p<0.001). TF (236.50±79.23)and TFPI (242.33±85.84)were significantly higher in group II, compared to group I (150.33±81.16), (152.8± 82.46), (p<0.001). TF and TFPI were significantly correlated to body mass index and glycemic control. Also, TF and TFPI were significantly higher in hypertensives (p=0.001) and dyslipidemics (p=0.006) but not in smokers (p=0.64), (p=0.11) respectively.
There was a correlation between high TF, TFPI plasma levels, FVIIa activity and cardiothrombotic complications in T2DM especially in the presence of high risk factors such as poor glycemic control, dyslipidemia and obesity. Future target therapy against TF may be beneficial for T2DM patients.
组织因子(TF)是通过激活因子VII(FVII)启动外源性凝血途径的主要物质,其在生理状态下受到组织因子途径抑制剂(TFPI)的抑制。2型糖尿病(T2DM)患者中已发现该途径存在改变。本研究旨在评估T2DM患者血浆中TF、TFPI水平及FVII凝血活性(FVIIa)与心脏血栓性疾病的关系,以及它们与患者代谢和临床特征的相关性。
该研究纳入80例T2DM患者,分为两组;第一组:40例无心脏病病史且临床检查未发现心脏病的患者,第二组:40例有心肌梗死病史的患者,同时选取30例对照。2007年9月至2009年2月期间,在获得知情同意后,从艾因夏姆斯大学糖尿病诊所招募患者。采集外周血样本,采用ELISA技术检测血浆TF和TFPI水平,使用缺乏FVII的血浆检测FVIIa定量。
与对照组相比,T2DM患者血浆TF、TFPI和FVIIa水平显著升高(p<0.001)。与第一组(150.33±81.16)、(152.8±82.46)相比,第二组的TF(236.50±79.23)和TFPI(242.33±85.84)显著升高(p<0.001)。TF和TFPI与体重指数及血糖控制显著相关。此外,高血压患者(p=0.001)和血脂异常患者(p=0.006)的TF和TFPI水平显著升高,但吸烟者中TF(p=0.64)和TFPI(p=0.11)水平无显著变化。
T2DM患者中,高血浆TF、TFPI水平及FVIIa活性与心脏血栓性并发症之间存在相关性,尤其是在存在血糖控制不佳、血脂异常和肥胖等高风险因素时。未来针对TF的靶向治疗可能对T2DM患者有益。